Comparing two HPV vaccines in teens and young adults in Zambia
Part of Cancer, Infections, Women’s health & pregnancy clinical trials.
This trial tests if a single dose of a locally made HPV vaccine (CERVAVAC) works as well as a single dose of the standard Gardasil vaccine. It is for girls and young women aged 9 to 20, and boys aged 9 to 14, in Zambia. The goal is to prevent HPV infection, which can cause cervical cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a girl or woman between 9 and 20 years old, or a boy between 9 and 14 years old.
- You are willing to follow the study rules and come for visits.
- You have never had an HPV vaccine before.
- You are not pregnant (if sexually active and of childbearing age).
- You do not have a weak immune system (like from HIV, cancer, or certain medications).
- You have no history of severe allergic reactions to vaccines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks how well two types of domestic HPV vaccines and one imported HPV vaccine boost your immune system. It is for girls aged 13-14 who have already finished their HPV vaccine shots about a month ago.
This study tests a 9-valent HPV vaccine (protects against 9 types of human papillomavirus) in women who have already completed a previous HPV vaccine series. Researchers will check how safe the new vaccine is and how well your immune system responds to it.
This study combines HPV vaccination with other health services for young people in Ivory Coast. It aims to protect adolescents against HPV, which can cause cancer, while also checking their overall health and well-being.
This trial tests a way to give HPV vaccines along with routine childhood immunizations in Ghana. It aims to protect against HPV, a virus that can cause cervical cancer, by making it easier to get the vaccine.
This study tests if a single dose of the HPV vaccine (Gardasil 9) can lower the amount of HPV virus in women who already have the virus, potentially reducing how easily it spreads. It will help us learn if vaccination can protect partners and communities.
This trial studies whether a quadrivalent HPV vaccine is safe and helps the body build protection (immunity) against HPV. It enrolls healthy Chinese females who are not already treated for HPV-related infection.
Hear when a new HPV Vaccination trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.